![]() |
|
|
Department of Cell Biology (M.H.H.), University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma; and Departments of Cell Biology (D.M.T., M.D.), and Chemistry (J.A.M., T.J.M.), University of Virginia, Charlottesville, Virginia
Previous studies have shown that cisplatin requires metabolic activation to
become nephrotoxic. The activation is proposed to be via the metabolism of a
glutathione-platinum conjugate to a cysteinyl-glycine-platinum conjugate,
which is further processed to a cysteine conjugate. Preincubating cisplatin
with glutathione (GSH), cysteinyl-glycine, or N-acetylcysteine (NAC)
results in a transient increase in the toxicity of cisplatin toward renal
proximal tubular cells. In this study, the preincubation solutions were
analyzed by high pressure liquid chromatography (HPLC), atomic absorption
spectrometry, and mass spectrometry (MS) to characterize the formation and
structure of the platinum conjugates. HPLC analysis of the cisplatin-GSH,
cisplatin-cysteinyl-glycine, and cisplatin-NAC preincubation solutions
revealed two new platinum-containing peaks in each of the solutions. MS-MS
analysis of the peaks revealed a diplatinum- and a monoplatinum conjugate in
each of the solutions. Analysis of the composition and toxicity of the
solutions with time showed that the transient increase in toxicity correlated
with the formation of the monoplatinum conjugate whereas prolonged
preincubation decreased toxicity and correlated with the formation of the
diplatinum conjugate. The monoplatinum-monoglutathione conjugate is a
substrate for
-glutamyl transpeptidase, an enzyme that is essential for
the nephrotoxicity of cisplatin. The monoplatinum-mono-NAC conjugate can be
deacetylated to a cysteine conjugate, which is a substrate for pyroxidol
phosphate (PLP)-dependent cysteine S-conjugate ß-lyase. This
PLP-dependent enzyme is proposed to catalyze the final step in the metabolic
activation of cisplatin. Identification of the structure and toxicity of these
conjugates further elucidates the metabolism of cisplatin to a
nephrotoxin.
This article has been cited by other articles:
![]() |
C. Peklak-Scott, P. K. Smitherman, A. J. Townsend, and C. S. Morrow Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin Mol. Cancer Ther., October 1, 2008; 7(10): 3247 - 3255. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Videhult, G. Laurell, I. Wallin, and H. Ehrsson Kinetics of Cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration. Experimental Biology and Medicine, November 1, 2006; 231(10): 1638 - 1645. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang and M. H. Hanigan Role of Cysteine S-Conjugate {beta}-Lyase in the Metabolism of Cisplatin J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 988 - 994. [Abstract] [Full Text] [PDF] |
||||